Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours

Muhammad, Rohaizak; Farndon, John

doi:10.1046/j.1445-2197.2002.02507.x

Cited by 22 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the PubMed database and congress abstract search and screening are presented in Figure . The review consisted of 40 publications, including 27 full‐length publications and 13 congress abstracts (Tables and ) . Thirty‐six (90%) of the publications reported on studies performed in Europe, three involved centers in Europe, the U.S., and India (including the two subgroup analyses studies and an open‐label extension [OLE] study from the core CLARINET study), one was performed in the U.S., and one was performed in Israel.…”

Section: Resultsmentioning

confidence: 99%

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Michael

Garcia-Carbonero

Weber³

et al. 2017

The Oncologist

View full text Add to dashboard Cite

Current clinical evidence shows that lanreotide Autogel has good antiproliferative activity with favorable safety and tolerability in patients with GEP-NETs, suggesting it should be considered as an early first-line treatment in this population. Further studies are needed to assess the potential benefits of higher doses and the use of lanreotide Autogel in combination therapy and as maintenance therapy in the absence of disease progression following other therapies. 2017;22:272-285 IMPLICATIONS FOR PRACTICE: This review presents the current clinical evidence for the antiproliferative activity of lanreotide Autogel in patients with midgut or pancreatic neuroendocrine tumors (NETs) and shows its effectiveness, safety, and tolerability in these patient populations. By systematically presenting all the clinical evidence, the review adds to existing publications by discussing results in a broad range of settings. The review also indicates future directions for investigation of the use of lanreotide Autogel in NETs originating in other locations, in combination therapy, or as maintenance therapy in progressive disease.

show abstract

Section: Resultsmentioning

confidence: 99%

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Michael

Garcia-Carbonero

Weber³

et al. 2017

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Hormone therapy is indicated in carcinoids causing functional symptoms, however, no evidence is available as to the control of disease progression. Moreover, this therapy might only exert cytostatic effects [23][24][25] . Indeed, evidence does exist demonstrating that somatostatin analogs can inhibit tumour growth, at least for a certain period of time [26,27] , but further studies are necessary to evaluate this effect.…”

Section: Discussionmentioning

confidence: 99%

Primary hepatic carcinoid: A case report and literature review

Fenoglio¹,

Severini²,

Ferrigno³

et al. 2009

WJG

View full text Add to dashboard Cite

Carcinoids are tumors derived from neuroendocrine cells and often produce functional peptide hormones. Approximately 54.5% arise in the gastrointestinal tract and frequently metastasize to the liver. Primary hepatic carcinoid tumors (PHCT) are extremely rare; only 95 cases have been reported. A 65-year-old man came to our attention due to occasional ultrasound findings in absence of clinical manifestations. His previous medical history, since 2003, included an echotomography of the dishomogeneous parenchymal area but no focal lesions. A computed tomography s c a n p e r fo r m e d i n 2 0 0 5 s h o w e d an enhanced pseudonodular-like lesion of about 2 cm. Cholangiomagnetic resonance imaging identified the lesion as a possible cholangiocarcinoma. No positive findings were obtained with positron emission tomography. Histology suggested a secondary localization in the liver caused by a low-grade malignant neuroendocrine tumor. Immunohistochemistry was positive for anti chromogranin antibodies, Ki67 antibodies and synaptophysin. Octreoscan scintigraphy indicated intense activity in the lesion. Endoscopic investigations were performed to exclude the presence of extrahepatic neoplasms. Diagnosis of PHCT was established. The patient underwent left hepatectomy, followed by hormone therapy with sandostatine LAR. Two months after surgery he had a lymph nodal relapse along the celiac trunk and caudate lobe, which was histologically confirmed. The postoperative clinical course was uneventful, with a negative follow-up for hematochemical, clinical and radiological investigations at 18 mo post-surgery. Diagnosis of PHCT is based principally on the histopathological confirmation of a carcinoid tumor and the exclusion of a non-hepatic primary tumor. Surgical resection is the recommended primary treatment for PHCT. Recurrence rate and survival rate in patients treated with resection were 18% and 74%, respectively.

show abstract

“…The anti-proliferative effect of lanreotide on KRJ-I proliferation is of interest; although some clinical studies have proposed that somatostatin analogues inhibit tumor growth (stabilization), the evidence has largely been equivocal and there appears to be inconsistent data when comparing in vitro studies, animal experiments, and clinical experience (Schally 1988, Patel et al 1995, Arnold et al 1996, Rohaizak & Farndon 2002, Modlin et al 2005, Plockinger et al 2005. It is likely that many of the apparent differences in tumor inhibitory data reflect the variety of models used as well as the numerous alternative regulatory pathways responsible for neoplastic cell proliferation and especially neuroendocrine neoplasia itself (Sippel & Chen 2002, Sippel et al 2003, Goke et al 2004, Van Gompel & Chen 2004, Hofsli et al 2005, Van Gompel et al 2005.…”

Section: Discussionmentioning

confidence: 99%

Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin

Kidd

Eick²,

Modlin³

et al. 2007

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Small intestinal carcinoids (SICs) are the most prevalent gastrointestinal carcinoid and characterized by local invasion metastasis and protean symptomatology. The proliferative and secretory regulation of the cell of origin, the enterochromaffin (EC) cell has not been characterized. The absence of either a pure preparation of normal EC cells or human EC carcinoid cell lines has hindered the development of therapeutic agents. We therefore further characterized the neoplastic SIC cell line, KRJ-I by assessing its secretory (serotonin (5-HT)) and proliferative responses and defining its log growth phase transcriptome. Electron microscopy demonstrated oval, lobulated nuclei and substance P, and 5-HT-positive cytoplasmic vesicles. RT-PCR detected transcripts for chromogranin A (CHGA), VMAT1 (SLC18A1), tryptophan hydroxylase (TPH1), substance P (TAC1), guanylin (GUCA2A), and SERT (SLC6A4). By immunohistochemistry, all cells were positive for CHGA, SERT, VMAT1, and TPH1. Transcriptome analysis (Affymetrix U133 Plus chips) identified somatostatin SSTR2/3, adrenergic a1C and b1, dopamine D2, nicotinic-type cholinergic A5, A6, B1, muscarinic acetylcholine M4, and 5-HT-2A receptors. The presence of transcripts for SSTR1, SSTR2, and SSTR3 receptors was confirmed by RT-PCR and sequencing. Isoproterenol (ISO) resulted in a dose-dependent increase in intracellular cAMP (EC 50 Z340 nM) and 5-HT (EC 50 Z81 nM) which was completely inhibited by the cAMP antagonist 2 0 ,5 0 -dideoxyadenosine (10 mM). Preincubation with a SSTR agonist, lanreotide, inhibited Ip-stimulated 5-HT secretion (IC 50 Z420 nM). Both lanreotide (10 nM) and rapamycin (50 nM) inhibited proliferation (20G12 and 35G5% respectively) in serum-free medium whereas gefitinib (1 nM-10 mM) inhibited proliferation at micromolar concentrations. KRJ-I is a neoplastic EC cell line that can be used as an in vitro model of SICs as it will allow elucidation and clarification of the secretory and proliferative mechanism(s) of neoplastic EC cells and the molecular signatures that characterize each of these responses.

show abstract

Use of octreotide and lanreotide in the treatment of symptomatic non‐resectable carcinoid tumours

Abstract: Octreotide and long-acting lanreotide are useful palliative treatments for the control of symptoms in patients with non-resectable carcinoid tumours but there is no evidence of tumour stasis.

Cited by 22 publications

References 27 publications

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Primary hepatic carcinoid: A case report and literature review

Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin

Contact Info

Product

Resources

About